KBY Biotech Indexv0.0.34
Search
← Pipeline|Tezeratamab

Tezeratamab

Phase 3
PRM-5051
By Prime Medicine
Source: Trial-derived·Trials: 3
Modality
Cell Therapy
MOA
USP1i
Target
CGRP
Pathway
Tau
AsthmaThymomaBreast Ca
Development Pipeline
Preclinical
~Nov 2016
→ ~Feb 2018
Phase 1
~May 2018
→ ~Aug 2019
Phase 2
~Nov 2019
→ ~Feb 2021
Phase 3
May 2021
→ Dec 2031
Phase 3Current
NCT06750175
1,283 pts·Breast Ca
2021-05→2031-07·Recruiting
NCT03412060
350 pts·Asthma
2021-12→2027-09·Active
NCT05859495
2,563 pts·Breast Ca
2023-06→2031-12·Recruiting
4,196 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2027-09-181.5y awayPh3 Readout· Asthma
2031-07-105.3y awayPh3 Readout· Breast Ca
2031-12-055.7y awayPh3 Readout· Breast Ca
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P3
Recruit…
P3
Active
P3
Recruit…
Catalysts
Ph3 Readout
2027-09-18 · 1.5y away
Asthma
Ph3 Readout
2031-07-10 · 5.3y away
Breast Ca
Ph3 Readout
2031-12-05 · 5.7y away
Breast Ca
RecruitingActive|StartCompletionToday
Trials (3)
NCTPhaseIndicationStatusNEP
NCT06750175Phase 3Breast CaRecruiting1283VA
NCT03412060Phase 3AsthmaActive350MRD
NCT05859495Phase 3Breast CaRecruiting2563UPCR
Competitors (10)
DrugCompanyPhaseTargetMOA
SNY-2934SanofiPhase 3KRASG12DUSP1i
TAK-9344TakedaPhase 3CGRPHER2
AMG-9052AmgenPhase 2/3CDK2USP1i
DatozumabRegeneronPhase 1B7-H3USP1i
ZenotinibBioNTechPhase 1CGRPAnti-Aβ
CapiglumideBioNTechPreclinicalCGRPMDM2i
BII-4342BiogenPhase 2/3CGRPCAR-T CD19
GMA-729GenmabPhase 2BCL-2USP1i
LEG-9870Legend BiotechPhase 1CGRPPARPi
PexanaritideInnovent BioPreclinicalSGLT2USP1i